Hints and tips:
Related Special Reports
...The deal settles civil allegations against its US arm, Novartis Pharmaceuticals Corporation, and is the company’s third big resolution with US authorities in recent months....
...Incyte, a US biotech group, had hoped to prove that combining its experimental immunotherapy with Keytruda — a leading checkpoint inhibitor made by its Big Pharma partner Merck — would boost survival rates...
...Both Merck and Bristol-Myers are testing their checkpoints in combination with this type of medicine in a partnership with Incyte, a US biotech group that is developing the most advanced IDO inhibitor....
...“It’s not bad to be sexy — you want to be wanted,” says Hervé Hoppenot, the French-born chief executive of Incyte and previously president of oncology at Novartis....
...“When you’re dealing with agents that are going to stimulate the body, you have to be careful,” says Dr Steven Stein, chief medical officer at Incyte, a biotech focused on cancer drugs....
...Amgen, for instance, is trying to launch the first biosimilar of Humira, while simultaneously fighting the introduction of a copycat version of its drug, Enbrel, by Novartis, the Swiss pharma group....
...The case is the latest example of corporations using their right to free speech under the first amendment to block attempts by regulators to curtail their marketing efforts....
...The real problem, though, is that a brilliant pharma executive has allowed himself to be gagged. Mr Vasella’s sense of his worth appears to have deserted him this time....
...for Novartis of Switzerland....
...When Novartis started the trend in 2005, with its €5.7bn acquisition of generic-maker Hexal EonLabs, many were sceptical....
...Daniel Vasella, although only 53, has become the doyen of the sector, a decade after he was named the first chief executive of Novartis, the Swiss group formed by the merger of Sandoz and Ciba-Geigy, in...
International Edition